NEMO: A phase 3 trial of binimetinib (MEK162) versus dacarbazine in patients with untreated or progressed after first-line immunotherapy unresectable or metastatic NRAS-mutant cutaneous melanoma.

Konference: 2014 50th ASCO Annual Meeting - účast ČR

Kategorie: Maligní melanom a nádory kůže

Téma: Postery

Číslo abstraktu: TPS9102

Autoři: Keith Flaherty; prof. MUDr. Petr Arenberger, DrSc., MBA; M.D. Paolo Antonio Ascierto (1964-); Jan Willem De Groot; M.D. Sigrun Hallmeyer; Prof. M.D. Georgina V. Long, BSc PhD MBBS FRACP; M.D. Michal Lotem; M.D. Maria Marples; Prof. M.D. Dirk Schadendorf; M.D. Alexander N. Starodub; M.D. Matthew Hiram Taylor; Pascal Wolter; M.D. Naoyai Yamazaki, Ph.D.; Ernesto Wasserman; James Ford; Marine Weill; Prof. M.D. Reinhard Dummer

Abstract:

Background: Melanoma tumors often harbor mutations in the mitogen-activated protein kinase-signaling pathway family members BRAF or NRAS. NRAS mutations, observed in about 15% of patients with melanoma, are associated with higher tumor proliferation and poorer prognoses. A large retrospective analysis (n = 677) demonstrated that NRAS mutations are independently predictive of poor survival in patients with cutaneous melanoma (Jakob et al., 2011). With no approved targeted therapies for melanoma patients with NRAS-mutant tumors, treatments are currently limited to chemotherapy and/or immunotherapy. Binimetinib (MEK162), a potent and selective inhibitor of MEK1/2, has demonstrated promising phase 2 clinical activity in this patient subset. Here we describe the “NRAS mElanoma and MEK inhibitOr” (NEMO) trial, an ongoing phase 3 study designed to compare the efficacy of binimetinib vs dacarbazine in patients with metastatic NRAS-mutant cutaneous melanoma (NCT01763164). 

Methods: NEMO is a 2-arm, open-label, 2:1 randomized trial of binimetinib vs dacarbazine. Eligible patients must have advanced unresectable or metastatic cutaneous melanoma with a documented NRAS Q61 mutation (by central molecular screening) that was previously untreated or has progressed after 1 line of immunotherapy. Patients are stratified by stage, performance status, and prior immunotherapy. The primary endpoint of the study is progression-free survival, and secondary endpoints include overall survival, overall response, disease control rate, safety, and quality of life. Binimetinib is administered orally at 45 mg twice daily and dacarbazine is dosed intravenously at 1000 mg/m2 once every 3 weeks, until disease progression or unacceptable toxicity. Patient crossover from the dacarbazine arm to the binimetinib arm is not permitted. This phase 3 trial is designed to enroll 393 patients and is currently recruiting patients at more than 150 centers worldwide. Clinical trial information: NCT01763164.

www.asco.org

Citation:
J Clin Oncol 32:5s, 2014 (suppl; abstr TPS9102)

Datum přednesení příspěvku: 31. 5. 2014